Pharmaceuticals News and Research

RSS

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Covance opens state-of-the-art biorepository facility at Greenfield

Covance Inc., a leading provider of drug development services, announced today that it has opened a state-of-the-art biorepository facility at its Greenfield, Indiana location. The 20,000-square-foot building is dedicated to long-term storage of clinical trial specimens. The facility is able to store a wide-range of specimens, including plasma, serum, whole blood, DNA, PBMC, and tissue.

9 Jun 2010

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

RoundTable signs agreement to acquire Ophthalmic Systems business unit

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the health-care industry, announced today that is has entered into an agreement with BD to acquire the Ophthalmic Systems unit, a business within the BD Medical segment. BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.

9 Jun 2010

IBM, ProtonMedia enter teaming agreement for 3-D virtual collaboration platform

IBM and ProtonMedia have entered into a teaming agreement that will result in the delivery of innovative, 3-D virtual collaboration and communication solutions engineered specifically for global life sciences organizations. Under the terms of the agreement, ProtonMedia's ProtoSphere technology will be the basis for customized, 3-D virtual collaboration environments to create high-performance workplaces.

9 Jun 2010

Research findings hold promise for debilitating emotional symptoms of FXS

The study, which appears in the journal the Proceedings of the National Academy of Sciences, is also of potential therapeutic significance-it showed that a brief pharmacological treatment is capable of correcting some of these synaptic deficits in mice genetically engineered to model FXS.

9 Jun 2010

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Abbott today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.

9 Jun 2010

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary bispecific antibody, has shown selective tumor localization and minimal normal tissue retention in two early Phase I studies in patients with colorectal cancer.

8 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Novartis Pharmaceutical Canada Inc. announced that Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by Health Canada for active immunization of adolescents (11 to 18 years of age) and adults (19 to 55 years of age) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

8 Jun 2010

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today announced the signing of an exclusive distribution agreement for the company's SmartChip Real-Time PCR System with Takeda Rika Kogyo Co., Ltd., a leading distributor of innovative products and services in the life science markets within Japan.

8 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.

8 Jun 2010

QOI selects multi-tenant SaaS CRM system from Veeva System

QLT Ophthalmics, Inc., a wholly-owned U.S. subsidiary of QLT Inc., selected Veeva System's multi-tenant SaaS CRM system built on the cloud computing model. QOI was formed by QLT Inc. in Q4 2009 to take over the sales and marketing of Visudyne in the U.S. from Novartis Pharma AG.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Jun 2010

Pharmaceuticals News and Research

Astellas Pharma acquires OSI Pharmaceuticals for $4.0 billion

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Blood vessel-blocking drug slows prostate cancer progression: Experts

Covance opens state-of-the-art biorepository facility at Greenfield

Pharnext closes €4.8-million Series A funding round

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

RoundTable signs agreement to acquire Ophthalmic Systems business unit

IBM, ProtonMedia enter teaming agreement for 3-D virtual collaboration platform

Research findings hold promise for debilitating emotional symptoms of FXS

Lubiprostone phase 3 clinical trial in Japan for chronic idiopathic constipation meets primary endpoint

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Health Canada approves Novartis' Menveo for prevention of meningococcal disease

Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Idera reports preliminary results from IMO-3100 Phase 1 clinical trial for autoimmune, inflammatory diseases

QOI selects multi-tenant SaaS CRM system from Veeva System

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News